H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $4.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX).

The analyst commented: "At ADA ’25, Lexicon presented results from a post-hoc analysis assessing the benefits of sotagliflozin on hypoglycemic events in T1D patients treated with insulin. Results correspond to a pooled analysis from the Phase 3 inTandem1 and inTandem2 clinical trials in T1D patients that evaluated daily doses of sotagliflozin (200 mg and 400 mg), vs. placebo, on top of optimized insulin therapy, during 52 weeks. In these studies, documented hypoglycemia was defined as blood glucose of ≤70 mg/dL and ≤55 mg/dL, and severe hypoglycemia per the ADA Level 3 definition. Data were evaluated by subgroups defined by estimated glomerular filtration rate (eGFR): eGFR <60 ml/min/1.73m2, eGFR ≥60 to <90 ml/min/1.73m2, and eGFR ≥90 ml/min/1.73m2. Sotagliflozin exhibited no increased risk, and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL (see below). Interestingly, sotagliflozin arm exhibited reduced hypoglycemia event rates vs. placebo, and the effects appeared consistent across eGFR subgroups, suggesting that sotagliflozin-mediated benefits are independent of kidney function. Recall, results from the inTandem studies led to the approval of ZYNQUISTA (sotagliflozin) for the management of T1D by the EMA in April 2019. Considering that hypoglycemia remains an important T1D management concern, we believe these results validate sotagliflozin’s efficacy not only for glycemic control but also for preventing hypoglycemia in these patients. Reiterate Buy rating and $4 PT."

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $0.73 yesterday.

You May Also Be Interested In

• SGHC Limited (SGHC) PT Raised to $19 at Citizens on Likely Upside to Q2 Estimates
• Flutter Entertainment (FLUT) PT Lowered to $159 at Citizens Amid Betfair Predicts Beta Test
• UBS Downgrades Castellum AB (CAST:SS) (CWQXF) to Neutral